organization · Reporting owner
Seventh MDV Partners, L.L.C.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adamas Pharmaceuticals IncADMS · Entity 133085 | 10% owner | September 14, 2016 | September 16, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adamas Pharmaceuticals Inc
Report date September 14, 2016 · Filed September 16, 2016
Jointly reported with MDV IX LP, Ninth MDV Partners, L.L.C., FEIBER JONATHAN D, SCHOENDORF NANCY J, MDV ENF VII (A), L.P., MDV ENF VII (B), L.P., MDV VII Leaders' Fund, L.P., MDV VII LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectMDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP | 4,031,804 |
Last balance in matching sequence
After 2016-09-16 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2016-09-14 · Purchase · Acquired 54,537 · Balance 4,023,364 F1: Price reflected is the weighted-average purchase price for shares purchased. The range of the purchase prices for the transaction was $16.22 and $16.50 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F2: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. Row 2 · 2016-09-15 · Purchase · Acquired 200 · Balance 4,023,564 F2: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. Row 3 · 2016-09-16 · Purchase · Acquired 8,240 · Balance 4,031,804 F3: Price reflected is the weighted-average purchase price for shares purchased. The range of the purchase prices for the transaction was $16.52 and $17.00 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F2: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectMDV VII, L.P. | 265,150 |
Reported balance
Holding disclosure · report date 2016-09-14 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 265,150 F2: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectMDV ENF VII (A), L.P. | 6,043 |
Reported balance
Holding disclosure · report date 2016-09-14 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 6,043 F2: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectMDV ENF VII (B), L.P. | 3,146 |
Reported balance
Holding disclosure · report date 2016-09-14 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 3,146 F2: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectMDV VII Leaders' Fund, L.P. | 25,661 |
Reported balance
Holding disclosure · report date 2016-09-14 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 25,661 F2: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectMDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P. | 287,992 |
Reported balance
Holding disclosure · report date 2016-09-14 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 287,992 F4: Ninth MDV Partners, L.L.C. is the general partner of MDV IX, L.P., as nominee for MDV IX, L.P. and MDV ENF IX, L.P. (collectively, "MDV IX"). William Ericson ("Ericson") and Jonathan Feiber ("Feiber") are Managing Members of Ninth MDV Partners, L.L.C. Ericson and Feiber may be deemed to share voting and dispositive power over the shares held by MDV IX. Each Reporting Person disclaims beneficial ownership of the shares held by MDV IX except to the extent of any pecuniary interest therein. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: Price reflected is the weighted-average purchase price for shares purchased. The range of the purchase prices for the transaction was $16.22 and $16.50 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F2: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
F3: Price reflected is the weighted-average purchase price for shares purchased. The range of the purchase prices for the transaction was $16.52 and $17.00 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F4: Ninth MDV Partners, L.L.C. is the general partner of MDV IX, L.P., as nominee for MDV IX, L.P. and MDV ENF IX, L.P. (collectively, "MDV IX"). William Ericson ("Ericson") and Jonathan Feiber ("Feiber") are Managing Members of Ninth MDV Partners, L.L.C. Ericson and Feiber may be deemed to share voting and dispositive power over the shares held by MDV IX. Each Reporting Person disclaims beneficial ownership of the shares held by MDV IX except to the extent of any pecuniary interest therein. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2016 Filed Sep 16, 2016 20:23 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | PurchaseCommon Stock | 8,240 | $16.81 | $138,497.10 |
DisclosureSEC source: 0001209191-16-141889 · doc4.xml · nonDerivative · entry 3 MDV IX LP · CIK 0001410787 · 10% owner Seventh MDV Partners, L.L.C. · CIK 0001564546 · 10% owner Ninth MDV Partners, L.L.C. · CIK 0001573991 · 10% owner FEIBER JONATHAN D · CIK 0001027621 · 10% owner SCHOENDORF NANCY J · CIK 0001250354 · 10% owner MDV ENF VII (A), L.P. · CIK 0001605837 · 10% owner MDV ENF VII (B), L.P. · CIK 0001605838 · 10% owner MDV VII Leaders' Fund, L.P. · CIK 0001605840 · 10% owner MDV VII LP · CIK 0001129541 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP Disclosed balance after: 4,031,804 F3 · price: Price reflected is the weighted-average purchase price for shares purchased. The range of the purchase prices for the transaction was $16.52 and $17.00 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| September 15, 2016 Filed Sep 16, 2016 20:23 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | PurchaseCommon Stock | 200 | $16.50 | $3,300.00 |
DisclosureSEC source: 0001209191-16-141889 · doc4.xml · nonDerivative · entry 2 MDV IX LP · CIK 0001410787 · 10% owner Seventh MDV Partners, L.L.C. · CIK 0001564546 · 10% owner Ninth MDV Partners, L.L.C. · CIK 0001573991 · 10% owner FEIBER JONATHAN D · CIK 0001027621 · 10% owner SCHOENDORF NANCY J · CIK 0001250354 · 10% owner MDV ENF VII (A), L.P. · CIK 0001605837 · 10% owner MDV ENF VII (B), L.P. · CIK 0001605838 · 10% owner MDV VII Leaders' Fund, L.P. · CIK 0001605840 · 10% owner MDV VII LP · CIK 0001129541 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP Disclosed balance after: 4,023,564 F2 · ownership.nature: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 20:23 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | PurchaseCommon Stock | 54,537 | $16.43 | $895,786.59 |
DisclosureSEC source: 0001209191-16-141889 · doc4.xml · nonDerivative · entry 1 MDV IX LP · CIK 0001410787 · 10% owner Seventh MDV Partners, L.L.C. · CIK 0001564546 · 10% owner Ninth MDV Partners, L.L.C. · CIK 0001573991 · 10% owner FEIBER JONATHAN D · CIK 0001027621 · 10% owner SCHOENDORF NANCY J · CIK 0001250354 · 10% owner MDV ENF VII (A), L.P. · CIK 0001605837 · 10% owner MDV ENF VII (B), L.P. · CIK 0001605838 · 10% owner MDV VII Leaders' Fund, L.P. · CIK 0001605840 · 10% owner MDV VII LP · CIK 0001129541 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP Disclosed balance after: 4,023,364 F1 · price: Price reflected is the weighted-average purchase price for shares purchased. The range of the purchase prices for the transaction was $16.22 and $16.50 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| September 13, 2016 Filed Sep 14, 2016 19:02 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | PurchaseCommon Stock | 62,034 | $15.56 | $964,994.70 |
DisclosureSEC source: 0001209191-16-141471 · doc4.xml · nonDerivative · entry 2 MDV IX LP · CIK 0001410787 · 10% owner Seventh MDV Partners, L.L.C. · CIK 0001564546 · 10% owner Ninth MDV Partners, L.L.C. · CIK 0001573991 · 10% owner FEIBER JONATHAN D · CIK 0001027621 · 10% owner SCHOENDORF NANCY J · CIK 0001250354 · 10% owner MDV ENF VII (A), L.P. · CIK 0001605837 · 10% owner MDV ENF VII (B), L.P. · CIK 0001605838 · 10% owner MDV VII Leaders' Fund, L.P. · CIK 0001605840 · 10% owner MDV VII LP · CIK 0001129541 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP Disclosed balance after: 3,968,827 F3 · price: Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $15.25 and $16.00 per share. The Reporting Persons undertake to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 19:02 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | PurchaseCommon Stock | 22,342 | $15.65 | $349,734.97 |
DisclosureSEC source: 0001209191-16-141471 · doc4.xml · nonDerivative · entry 1 MDV IX LP · CIK 0001410787 · 10% owner Seventh MDV Partners, L.L.C. · CIK 0001564546 · 10% owner Ninth MDV Partners, L.L.C. · CIK 0001573991 · 10% owner FEIBER JONATHAN D · CIK 0001027621 · 10% owner SCHOENDORF NANCY J · CIK 0001250354 · 10% owner MDV ENF VII (A), L.P. · CIK 0001605837 · 10% owner MDV ENF VII (B), L.P. · CIK 0001605838 · 10% owner MDV VII Leaders' Fund, L.P. · CIK 0001605840 · 10% owner MDV VII LP · CIK 0001129541 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP Disclosed balance after: 3,906,793 F1 · price: Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $15.26 and $15.75 per share. The Reporting Persons undertake to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 19:25 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | PurchaseCommon Stock | 60,846 | $15.68 | $954,065.28 |
DisclosureSEC source: 0001209191-16-140846 · doc4.xml · nonDerivative · entry 1 MDV IX LP · CIK 0001410787 · 10% owner Seventh MDV Partners, L.L.C. · CIK 0001564546 · 10% owner Ninth MDV Partners, L.L.C. · CIK 0001573991 · 10% owner FEIBER JONATHAN D · CIK 0001027621 · 10% owner SCHOENDORF NANCY J · CIK 0001250354 · 10% owner MDV ENF VII (A), L.P. · CIK 0001605837 · 10% owner MDV ENF VII (B), L.P. · CIK 0001605838 · 10% owner MDV VII Leaders' Fund, L.P. · CIK 0001605840 · 10% owner MDV VII LP · CIK 0001129541 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP Disclosed balance after: 3,884,451 F1 · price: Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $15.25 and $15.81 per share. The Reporting Persons undertake to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| September 06, 2016 Filed Sep 7, 2016 20:39 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | PurchaseCommon Stock | 7,200 | $15.00 | $107,979.84 |
DisclosureSEC source: 0001209191-16-140473 · doc4.xml · nonDerivative · entry 2 MDV IX LP · CIK 0001410787 · 10% owner Seventh MDV Partners, L.L.C. · CIK 0001564546 · 10% owner Ninth MDV Partners, L.L.C. · CIK 0001573991 · 10% owner FEIBER JONATHAN D · CIK 0001027621 · 10% owner SCHOENDORF NANCY J · CIK 0001250354 · 10% owner MDV ENF VII (A), L.P. · CIK 0001605837 · 10% owner MDV ENF VII (B), L.P. · CIK 0001605838 · 10% owner MDV VII Leaders' Fund, L.P. · CIK 0001605840 · 10% owner MDV VII LP · CIK 0001129541 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP Disclosed balance after: 3,823,605 F3 · price: Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $14.70 and $15.23 per share. The Reporting Persons undertake to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 20:39 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | PurchaseCommon Stock | 43,719 | $14.75 | $644,920.83 |
DisclosureSEC source: 0001209191-16-140473 · doc4.xml · nonDerivative · entry 1 MDV IX LP · CIK 0001410787 · 10% owner Seventh MDV Partners, L.L.C. · CIK 0001564546 · 10% owner Ninth MDV Partners, L.L.C. · CIK 0001573991 · 10% owner FEIBER JONATHAN D · CIK 0001027621 · 10% owner SCHOENDORF NANCY J · CIK 0001250354 · 10% owner MDV ENF VII (A), L.P. · CIK 0001605837 · 10% owner MDV ENF VII (B), L.P. · CIK 0001605838 · 10% owner MDV VII Leaders' Fund, L.P. · CIK 0001605840 · 10% owner MDV VII LP · CIK 0001129541 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP Disclosed balance after: 3,816,405 F1 · price: Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $14.54 and $15.00 per share. The Reporting Persons undertake to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.